Advanced in Seborrheic Keratosis

Dr. Janet C. Dubois

Dermatology
11671 Jollyville Rd, Ste 104, 
Austin, TX 
Advanced in Seborrheic Keratosis
11671 Jollyville Rd, Ste 104, 
Austin, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janet Dubois is a Dermatologist in Austin, Texas. Dr. Dubois is rated as an Advanced provider by MediFind in the treatment of Seborrheic Keratosis. Her top areas of expertise are Seborrheic Keratosis, Actinic Keratosis, Rosacea, and Acne.

Her clinical research consists of co-authoring 26 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Seborrheic Keratosis.

Specialties
Dermatology
Licenses
Dermatology in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

11671 Jollyville Rd, Ste 104, Austin, TX 78759

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Enrollment Status: Completed
Publish Date: August 29, 2024
Intervention Type: Drug
Study Drug: QTORIN rapamycin anhydrous gel
Study Phase: Phase 3
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
A Randomized, Observer-Blinded, Within Patient Bilateral Comparison to Study the Safety and Efficacy of Daily Application for 4 Weeks of DBI-001 Gel Versus Aqueous Gel in Subjects With Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2023
Intervention Type: Biological
Study Phase: Phase 2
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Phase 2a Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of NFX-179 Gel in Subjects With Cutaneous Neurofibromas
Enrollment Status: Completed
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drug: NFX-179
Study Phase: Phase 2
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
Enrollment Status: Completed
Publish Date: July 15, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
Enrollment Status: Terminated
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
A Phase 1b, Multicenter, Open-Label, Parallel-Group, Maximal Use Systemic Exposure (MUSE) Study to Evaluate the Pharmacokinetics, Safety and Tolerability of S6G5T-3 Compared to Retin-A® 0.1% in Subjects With Moderate to Severe Acne Vulgaris
Enrollment Status: Completed
Publish Date: March 18, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults
Enrollment Status: Completed
Publish Date: May 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP
Enrollment Status: Withdrawn
Publish Date: November 07, 2017
Intervention Type: Drug, Device
Study Phase: Phase 3
View 9 Less Clinical Trials

26 Total Publications

NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
NivobotulinumtoxinA in the Treatment of Lateral Canthal Lines Alone and With Concurrent Treatment of Glabellar Lines.
Journal: Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Published: September 09, 2025
Similar Doctors
Distinguished in Seborrheic Keratosis
Dr. Mollie M. Jan
Dermatology
Distinguished in Seborrheic Keratosis
Dr. Mollie M. Jan
Dermatology

Mountain West Derm - Blackhart PLLC

4513 Williams Dr, 
Georgetown, TX 
 (18.5 miles away)
512-930-3909
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Mollie Jan is a Dermatologist in Georgetown, Texas. Dr. Jan is rated as a Distinguished provider by MediFind in the treatment of Seborrheic Keratosis. Her top areas of expertise are Seborrheic Keratosis, Warts, Actinic Keratosis, and Liver Spots. Dr. Jan is currently accepting new patients.

Distinguished in Seborrheic Keratosis
Dr. Matthew T. Smetanick
Dermatology
Distinguished in Seborrheic Keratosis
Dr. Matthew T. Smetanick
Dermatology

Mountain West Derm - Blackhart PLLC

200 County Rd, 340a Suite B, 
Burnet, TX 
 (36.9 miles away)
512-756-2525
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Matthew Smetanick is a Dermatologist in Burnet, Texas. Dr. Smetanick is rated as a Distinguished provider by MediFind in the treatment of Seborrheic Keratosis. His top areas of expertise are Seborrheic Keratosis, Warts, Actinic Keratosis, and Liver Spots. Dr. Smetanick is currently accepting new patients.

Distinguished in Seborrheic Keratosis
Dr. Amara Z. Sayed
Dermatology
Distinguished in Seborrheic Keratosis
Dr. Amara Z. Sayed
Dermatology

Mountain West Derm - Blackhart PLLC

4513 Williams Dr, 
Georgetown, TX 
 (18.5 miles away)
512-930-3909
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Amara Sayed is a Dermatologist in Georgetown, Texas. Dr. Sayed is rated as a Distinguished provider by MediFind in the treatment of Seborrheic Keratosis. Her top areas of expertise are Actinic Keratosis, Universal Acquired Melanosis, Liver Spots, and Warts. Dr. Sayed is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dubois's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile